Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (311-320 of 333) with videos related to

Pageof 34
Sort By:
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Journal of Hepatology|October 27, 2016
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationAdriaan J van der Meer, Jordan J Feld, Harald Hofer, et al.
Gastroenterology|December 20, 2015
Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis BJang-June Park, David K Wong, Abdus S Wahed, et al.
The Lancet. Respiratory Medicine|October 14, 2019
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trialMarcelo Cypel, Jordan J Feld, Marcos Galasso, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
The American Journal of Gastroenterology|January 31, 2023
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 21, 2022
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis BHannah S J Choi, Grishma Hirode, Chien-Hung Chen, et al.
Pageof 34

Showing results (311-320 of 333) with videos related to

Sort By:
Pageof 34
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Journal of Hepatology|October 27, 2016
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationAdriaan J van der Meer, Jordan J Feld, Harald Hofer, et al.
Gastroenterology|December 20, 2015
Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis BJang-June Park, David K Wong, Abdus S Wahed, et al.
The Lancet. Respiratory Medicine|October 14, 2019
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trialMarcelo Cypel, Jordan J Feld, Marcos Galasso, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
The American Journal of Gastroenterology|January 31, 2023
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 21, 2022
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis BHannah S J Choi, Grishma Hirode, Chien-Hung Chen, et al.
Pageof 34